Radiolabeling of Herceptin with 99mTc as a Her2 tracer

Samira Heydari, Hossein Rajabi, Samira Rasaneh, Fariba Johari Daha
2014 Novelty in Biomedicine  
Trastuzumab is a monoclonal antibody that is used in treating breast cancer. We labeled this monoclonal antibody with Technetium-99m and performed in vitro and in vivo quality control tests as a first step in the production of a new radiopharmaceutical. Methods: Trastuzumab was labeled with Technetium-99m using Succinimidyl Hydrazinonicotinamide (HYNIC) as chelator. Radiochemical Purity and stability in buffer and serum were determined. Immunoreactivity and toxicity of the complex were tested
more » ... mplex were tested on SKBR3, MCF7 and A431 breast cancer cell lines. Biodistribution study was performed in normal mice at 4 and 24 h post injection.Results: The radiochemical purity of the complex was 95±1.4%. The stabilities in phosphate buffer and in human blood serum at 24 h post preparation were 85±3.5% and 74±1.2%, respectively. The immunoreactivity of the complex was 86±1.4%. The binding of labeled antibody to the surface of SKBR3, MCF7 and A431 cells were increased by increasing Her2 concentration on the cells surface.Conclusions: The findings showed that the new radiopharmaceutical can be a promising candidate as Her2 antigen scanning for human breast cancer.
doaj:0d9d0c1f335c455a9959146f986c5d0f fatcat:7dzghkmxqrdgpattv3j5thfisy